"Scemblix® Outperforms Standard Treatment in Phase III Trial for Chronic Myeloid Leukemia"
Novartis announced positive results from the ASC4FIRST Phase III trial, showing that Scemblix (asciminib) demonstrated superior major molecular response (MMR) rates compared to standard-of-care tyrosine kinase inhibitors (TKIs) in newly diagnosed patients with chronic myeloid leukemia. The trial met both primary endpoints, with Scemblix showing favorable safety and tolerability profiles. These results suggest that Scemblix may offer a well-tolerated and highly efficacious treatment option for patients with chronic myeloid leukemia, addressing the unmet need for tolerable therapies that allow patients to balance treatment with their quality of life.